Lassman, Andrew B. http://orcid.org/0000-0001-7386-9928
Aldape, Kenneth D.
Ansell, Peter J.
Bain, Earle
Curran, Walter J.
Eoli, Marica
French, Pim J.
Kinoshita, Manabu
Looman, Jim
Mehta, Minesh
Muragaki, Yoshihiro
Narita, Yoshitaka
Ocampo, Christopher
Roberts-Rapp, Lisa
Song, Minghao
Vogelbaum, Michael A.
Walenkamp, Annemiek M. E.
Wang, Tony J. C.
Zhang, Peixin
van den Bent, Martin J.
Funding for this research was provided by:
AbbVie
NCI (P30CA013696, UG1CA189960)
Voices Against Brain Cancer
William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian Hospital
Article History
Received: 24 April 2019
Accepted: 16 June 2019
First Online: 4 July 2019
Compliance with ethical standards
:
: Andrew B. Lassman: In the last 36 months, Dr. Lassman reports grants, personal fees and non-financial support from AbbVie, during the conduct of the study; personal fees and non-financial support from Orbus, grants, personal fees and non-financial support from Karyopharm, personal fees and non-financial support from NW Biotherapeutics, grants and non-financial support from Oncoceutics, personal fees and non-financial support from Agios, personal fees and non-financial support from Celgene, personal fees and non-financial support from Novocure, non-financial support from Tocagen, non-financial support from BMS, grants, personal fees and non-financial support from Kadmon, grants, personal fees and non-financial support from Roche/Genentech, grants and non-financial support from Amgen, grants and non-financial support from Millenium, grants and non-financial support from Celldex, grants and non-financial support from Novartis, grants and non-financial support from Pfizer, non-financial support from Keryx/Aeterna Zentaris, grants and non-financial support from VBI Vaccines, grants and non-financial support from Beigene, personal fees from Bioclinica as an expert blinded independent reviewer of clinical and imaging data for a BMS-sponsored trial, personal fees from prIME Oncology, personal fees from Sapience, personal fees from WebMD, personal fees from Physicians' Education Resource/Chemotherapy Foundation Symposium, personal fees from Astra Zeneca, personal fees from Cortice, outside the submitted work. Kenneth D. Aldape: Nothing to disclose. Peter J. Ansell, Earle Bain, Jim Looman, Christopher Ocampo, Lisa Roberts-Rapp: Employees of AbbVie and may own stock/options. Walter J. Curran: Consultant for AstraZeneca and BMS; ownership shares of Nanthealth. Marica Eoli: Nothing to disclose. Pim J. French: Research funding from AbbVie. Manabu Kinoshita: Honoraria from Eisai, BrainLab, Nihon Medi-Physics, Canon Medical Systems, Integra Japan, Novocure, Daiichi-Sankyo, Chugai; research grants from Chugai, Daiichi-Sankyo, Takeda, Ohtsuka. Minesh Mehta: Consultant for Agenus, Insys, Remedy, IBA, Varian, Celgene, AbbVie, AstraZeneca, Tocagen, Blue Earth Diagnostics; board of directors with stock options, Oncoceutics. Yoshihiro Muragaki: Consulting/advisory role for AbbVie, Daiichi Sankyo; speakers’ bureau for MSD, Daiichi Sankyo, Chugai Pharma, Otsuka, Eisai, Novartis, Hitachi, Bristol-Myers Squibb Japan; research funding to institution from MSD, Daiichi Sankyo, Chugai Pharma, Otsuka, Eisai, Hitachi. Yoshitaka Narita: Grants and lectures fees from Chugai Pharmaceutical Co., Ono Pharmaceutical Co., AbbVie, Dainippon-Sumitomo, Daiichi Sankyo, Eisai, Stella-Pharma, Ohtuka, Meiji-Seika, SBI Pharma. Minghao Song: Employee of Abbott Molecular and may own stock/options. Michael A. Vogelbaum: Indirect equity and royalty interests in Infuseon Therapeutics, Inc. Annemiek Walenkamp: Research grants from Novartis, Ipsen; advisory board member for Ipsen, Novartis, Polyphor, Karyopharm; study budget from Karyopharm, BMS, Genzyme, Roche. Tony J. C. Wang: Personal fees and non-financial support from AbbVie; outside of the submitted work, consultant for Elekta, Merck, Doximity; advisory board and travel expenses for Novocure, AstraZeneca; honoraria from Elekta, Cancer Panels; stock options from Doximity; royalties from Wolters Kluwer. Peixin Zhang: Nothing to disclose. Martin J. van den Bent: Personal fees from AbbVie, Celgene, Genenta, BMS, Agios, Boehringer Ingelheim; research funding from AbbVie.